The Traderszone Network

Published in TZ Latest News 13 March, 2016 by The TZ Newswire Staff

Here’s Why Sarepta Therapeutics’ Shares Rebounded in February

The biotech’s shares bounced back last month after the FDA extended the review period for eteplirsen.